Read all of this leaflet carefully before you receive this vaccine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Comirnaty is and what it is used for
2. What you need to know before you receive Comirnaty
3. How Comirnaty is given
4. Possible side effects
5. How to store Comirnaty
6. Contents of the pack and other information

1. What Comirnaty is and what it is used for

Comirnaty is a vaccine used for preventing COVID-19 caused by SARS-CoV-2 virus.

Comirnaty is given to adults and adolescents from 12 years of age and older.

The vaccine causes the immune system (the body’s natural defences) to produce antibodies and blood cells that work against the virus, so giving protection against COVID-19.

As Comirnaty does not contain the virus to produce immunity, it cannot give you COVID-19.

2. What you need to know before you receive Comirnaty

Comirnaty should not be given

- if you are allergic to the active substance or any of the other ingredients of this medicine (listed in section 6)

Warnings and precautions

Talk to your doctor, pharmacist or nurse before you are given the vaccine if:

- you have ever had a severe allergic reaction or breathing problems after any other vaccine injection or after you were given Comirnaty in the past.
- you have ever fainted following any needle injection.
- you have a severe illness or infection with high fever. However, you can have your vaccination if you have a mild fever or upper airway infection like a cold.
- you have a bleeding problem, you bruise easily or you use a medicine to prevent blood-clots.
- you have a weakened immune system, because of a disease such as HIV infection or a medicine such as corticosteroid that affects your immune system

As with any vaccine, the 2-dose vaccination course of Comirnaty may not fully protect all those who receive it and it is not known how long you will be protected.

Children

Comirnaty is not recommended for children aged under 12 years.
Other medicines and Comirnaty
Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines or have recently received any other vaccine.

Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before you receive this vaccine.

Driving and using machines
Some of the effects of vaccination mentioned in section 4 (Possible side effects) may temporarily affect your ability to drive or use machines. Wait until these effects have worn off before you drive or use machines.

Comirnaty contains potassium and sodium
This vaccine contains less than 1 mmol potassium (39 mg) per dose, that is to say essentially ‘potassium-free’.

This vaccine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium-free’.

3. How Comirnaty is given
Comirnaty is given after dilution as an injection of 0.3 mL into a muscle of your upper arm.

You will receive 2 injections.

It is recommended to receive the second dose of the same vaccine 3 weeks after the first dose to complete the vaccination course.

If you have any further questions on the use of Comirnaty, ask your doctor, pharmacist or nurse.

4. Possible side effects
Like all vaccines, Comirnaty can cause side effects, although not everybody gets them.

**Very common side effects:** may affect more than 1 in 10 people
- injection site: pain, swelling
- tiredness
- headache
- muscle pain
- chills
- joint pain
- diarrhoea
- fever

Some of these side effects were slightly more frequent in adolescents 12 to 15 years than in adults.

**Common side effects:** may affect up to 1 in 10 people
- injection site redness
- nausea
- vomiting
Uncommon side effects: may affect up to 1 in 100 people
- enlarged lymph nodes
- feeling unwell
- arm pain
- insomnia
- injection site itching
- allergic reactions such as rash or itching

Rare side effects: may affect up to 1 in 1,000 people
- temporary one sided facial drooping
- allergic reactions such as hives or swelling of the face

Not known (cannot be estimated from the available data)
- severe allergic reaction

Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly to FDA Philippines via online reporting through the FDA Philippines website at https://www.fda.gov.ph/pharmacovigilance/ and include batch/lot number if available. By reporting side effects you can help provide more information on the safety of this medicine.

In addition, you can report side effects to Pfizer, Inc. at the contact information provided below.

<table>
<thead>
<tr>
<th>Email</th>
<th>Fax number</th>
<th>Contact numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="mailto:PHLAEReporting@pfizer.com">PHLAEReporting@pfizer.com</a></td>
<td>1 800 1110 1520 (Toll Free)</td>
<td>+63 9175171575</td>
</tr>
<tr>
<td></td>
<td></td>
<td>+63 2 8451 9288</td>
</tr>
<tr>
<td></td>
<td></td>
<td>+63 2 8415 9200 ext 19288</td>
</tr>
</tbody>
</table>

5. How to store Comirnaty

Keep this medicine out of the sight and reach of children.

The following information about storage, expiry and use and handling is intended for healthcare professionals.

Do not use this medicine after the expiry date which is stated on the carton and label after EXP. The expiry date refers to the last day of that month.

Store in freezer at -90 °C to -60 °C. Within the 6 months shelf-life unopened vials may be stored and transported at -25 °C to -15 °C for a single period of up to 2 weeks and can be returned to -90 °C to -60 °C.

Store in the original package in order to protect from light.

Transfers of frozen vials stored at ultra-low temperature (< -60 °C)
- Closed-lid vial trays containing 195 vials removed from ultra-low temperature frozen storage (< -60 °C) may be at temperatures up to 25 °C for up to 5 minutes.
- Open-lid vial trays, or vial trays containing less than 195 vials, removed from ultra-low temperature frozen storage (< -60 °C) may be at temperatures up to 25 °C for up to 3 minutes.
- After vial trays are returned to frozen storage following temperature exposure up to 25 °C, they
must remain in frozen storage for at least 2 hours before they can be removed again.

**Transfers of frozen vials stored at -25 °C to -15 °C**

- Closed-lid vial trays containing 195 vials removed from frozen storage (-25 °C to -15 °C) may be at temperatures up to 25 °C for up to 3 minutes.
- Open-lid vial trays, or vial trays containing less than 195 vials, removed from frozen storage (-25 °C to -15 °C) may be at temperatures up to 25 °C for up to 1 minute.

Once a vial is removed from the vial tray, it should be thawed for use.

After thawing, the vaccine should be diluted and used immediately. However, in-use stability data have demonstrated that once removed from freezer, the undiluted vaccine can be stored for up to 1 month at 2 °C to 8 °C. Within the 1-month shelf-life at 2 °C to 8 °C, up to 12 hours may be used for transportation. Prior to use, the unopened vaccine can be stored for up to 2 hours at temperatures up to 30 °C.

After dilution, store and transport the vaccine at 2 °C to 30 °C and use within 6 hours. Discard any unused vaccine.

Once removed from the freezer and diluted, the vials should be marked with the new discard date and time. Once thawed, the vaccine cannot be re-frozen.

Do not use this vaccine if you notice particulates in the dilution or discoloration.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. **Contents of the pack and other information**

**What Comirnaty contains**

- The active substance is COVID-19 mRNA Vaccine. After dilution, the vial contains 6 doses of 0.3 mL with 30 micrograms mRNA each.
- The other ingredients are:
  - ((4-hydroxybutyl)azanediy1)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315)
  - 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159)
  - 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC)
  - cholesterol
  - potassium chloride
  - potassium dihydrogen phosphate
  - sodium chloride
  - disodium phosphate dihydrate
  - sucrose
  - water for injections

**What Comirnaty looks like and contents of the pack**

The vaccine is a white to off-white dispersion (pH: 6.9 - 7.9) provided in a multidose vial of 6 doses in a 2 mL clear vial (type I glass), with a rubber stopper and a flip-off plastic cap with aluminium seal.

Pack size: 195 vials

**Manufacturers**

BioNTech Manufacturing GmbH
Kupferbergterrasse 17 - 19
55116 Mainz
Germany

Pfizer Manufacturing Belgium NV
Rijksweg 12
2870 Puurs
Belgium

For any information about this medicine, please contact the Emergency Use Authorization Holder:
Pfizer, Inc.
18F – 20F 8 Rockwell Building
Hidalgo Drive, Rockwell Center
Makati City, Metro Manila
Philippines
Fax number: 1 800 1110 1520 (Toll Free)
Contact numbers: +63 917 517 1575, +63 2 8451 9288, +63 2 8415 9200 ext 19288

You may submit medical information enquiries to https://pmiform.com/CONS/PH or to
MIS.Inquiry@Pfizer.com.

Scan the code with a mobile device to get the latest version of the package leaflet.

URL: www.comirnatyglobal.com
The following information is intended for healthcare professionals only:

Administer Comirnaty intramuscularly after dilution as a course of 2 doses (0.3 mL each) 3 weeks apart.

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Handling instructions

Comirnaty should be prepared by a healthcare professional using aseptic technique to ensure the sterility of the prepared dispersion.

<table>
<thead>
<tr>
<th>THAWING PRIOR TO DILUTION</th>
</tr>
</thead>
</table>

- The multidose vial is stored frozen and must be thawed prior to dilution. Frozen vials should be transferred to an environment of 2 °C to 8 °C to thaw; a 195 vial pack may take 3 hours to thaw. Alternatively, frozen vials may also be thawed for 30 minutes at temperatures up to 30 °C for immediate use.
- The unopened vial can be stored for up to 1 month at 2 °C to 8 °C. Within the 1-month shelf-life at 2 °C to 8 °C, up to 12 hours may be used for transportation.
- Allow the thawed vial to come to room temperature and gently invert it 10 times prior to dilution. Do not shake.
- Prior to dilution, the thawed dispersion may contain white to off-white opaque amorphous particles.
The thawed vaccine must be diluted in its original vial with 1.8 mL sodium chloride 9 mg/mL (0.9%) solution for injection, using a 21 gauge or narrower needle and aseptic techniques.

Equalise vial pressure before removing the needle from the vial stopper by withdrawing 1.8 mL air into the empty diluent syringe.
- Gently invert the diluted dispersion 10 times. Do not shake.
- The diluted vaccine should present as an off-white dispersion with no particulates visible. Do not use the diluted vaccine if particulates or discolouration are present.

<table>
<thead>
<tr>
<th>Gently × 10</th>
</tr>
</thead>
</table>

- The diluted vials should be marked with the appropriate date and time.
- After dilution, store at 2 ºC to 30 ºC and use within 6 hours, including any transportation time.
- Do not freeze or shake the diluted dispersion. If refrigerated, allow the diluted dispersion to come to room temperature prior to use.

| Record appropriate date and time. Use within 6 hours after dilution. |
PREPARATION OF INDIVIDUAL 0.3 mL DOSES OF COMIRNATY

- After dilution, the vial contains 2.25 mL from which 6 doses of 0.3 mL can be extracted.
- Using aseptic technique, cleanse the vial stopper with a single-use antiseptic swab.
- Withdraw 0.3 mL of Comirnaty.

Low dead-volume syringes and/or needles should be used in order to extract 6 doses from a single vial. The low dead-volume syringe and needle combination should have a dead volume of no more than 35 microlitres.

If standard syringes and needles are used, there may not be sufficient volume to extract a sixth dose from a single vial.
- Each dose must contain 0.3 mL of vaccine.
- If the amount of vaccine remaining in the vial cannot provide a full dose of 0.3 mL, discard the vial and any excess volume.
- Discard any unused vaccine within 6 hours after dilution.

Disposal
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.